638
B.I. Roman et al. / European Journal of Medicinal Chemistry 101 (2015) 627e639
discovery e past, present and future, Nat. Rev. Drug Disc. 13 (2014) 588e602,
d) J. Eder, R. Sedrani, C. Wiesmann, The discovery of first-in-class drugs: or-
for the validation, for regulatory purposes, of (quantitative) structureeactivity
[19] a) R.H. Rohrbaugh, P.C. Jurs, Descriptions of molecular shape applied in studies
of structure/activity and structure/property relationships, Anal. Chim. Acta
[9] M.E. Bracke, B.I. Roman, C.V. Stevens, L.M. Mus, V.S. Parmar, O. De Wever,
Chick heart invasion assay for testing the invasiveness of cancer cells and the
activity of potentially anti-invasive compounds, J. Vis. Exp. (2015) e52792,
[10] a) M.M. Mareel, M. De Mets, Effect of microtubule inhibitors on invasion and
on related activities of tumor cells, Int. Rev. Cytol. 90 (1984) 125e168, http://
[20] a) A. Golbraikh, A. Tropsha, Beware of q2!, J. Mol. Graph. Model 20 (2002)
b) A. Golbraikh, M. Shen, Z. Xiao, Y.-D. Xiao, K.-H. Lee, A. Tropsha, Rational
selection of training and test sets for the development of validated QSAR
b) S.A. Eccles, A. Massey, F.I. Raynaud, S.Y. Sharp, G. Box, M. Valenti,
L. Patterson, A. de Haven Brandon, S. Gowan, F. Boxall, W. Aherne,
M. Rowlands, A. Hayes, V. Martins, F. Urban, K. Boxall, C. Prodromou, L. Pearl,
K. James, T.P. Matthews, K.M. Cheung, A. Kalusa, K. Jones, E. McDonald,
X. Barril, P.A. Brough, J.E. Cansfield, B. Dymock, M.J. Drysdale, H. Finch,
R. Howes, R.E. Hubbard, A. Surgenor, P. Webb, M. Wood, L. Wright,
P. Workman, NVP-AUY922: a novel heat shock protein 90 inhibitor active
against xenograft tumor growth, angiogenesis, and metastasis, Cancer Res. 68
c) C. Sessa, G.I. Shapiro, K.N. Bhalla, C. Britten, K.S. Jacks, M. Mita,
V. Papadimitrakopoulou, T. Pluard, T.A. Samuel, M. Akimov, C. Quadt,
C. Fernandez-Ibarra, H. Lu, S. Bailey, S. Chica, U. Banerji, First-in-human phase
I dose-escalation study of the HSP90 inhibitor AUY922 in patients with
advanced solid tumors, Clin. Cancer Res. 19 (2013) 3671e3680, http://
[21] a) T.P. Robinson, R.B. Hubbard IV, T.J. Ehlers, J.L. Arbiser, D.J. Goldsmith,
J.P. Bowen, Synthesis and biological evaluation of aromatic enones related to
[22] a) Y. Jahng, L.-X. Zhao, Y.-S. Moon, A. Basnet, E.-k. Kim, H.W. Chang, H.K. Ju,
T.C. Jeong, E.-S. Lee, Simple aromatic compounds containing propenone
moiety show considerable dual COX/5-LOX inhibitory activities, Bioorg. Med.
Chem.
Lett.
14
(2004)
2559e2562,
b) P.M. Sivakumar, S.K.G. Babu, V. Sharm, M. Doble, QSAR and docking studies
on propenone derivatives as dual COX and 5-LOX inhibitors, Lett. Org. Chem. 5
[23] a) P. Rani, V.K. Srivastava, A. Kumar, Synthesis and antiinflammatory activity
of heterocyclic indole derivatives, Eur. J. Med. Chem. 39 (2004) 449e452,
[11] a) B.W. Vanhoecke, H.T. Depypere, A. De Beyter, S.K. Sharma, V.S. Parmar,
D. De Keukeleire, M.E. Bracke, New anti-invasive compounds: results from the
Indo-Belgian screening program, Pure Appl. Chem. 77 (2005) 65e74, http://
b) M.E. Bracke, B.W.A. Vanhoecke, L. Derycke, S. Bolca, S. Possemiers,
A. Heyerick, C.V. Stevens, D. De Keukeleire, H.T. Depypere, W. Verstraete,
C.A. Williams, S.T. McKenna, S. Tomar, D. Sharma, A.K. Prasad, A.L. DePass,
V.S. Parmar, Plant polyphenolics as anti-invasive cancer agents, Anticancer
b) D. Kumar, N.M. Kumar, K. Akamatsu, E. Kusaka, H. Harada, T. Ito, Synthesis
and biological evaluation of indolyl chalcones as antitumor agents, Bioorg.
Agents Med. Chem.
8
[24] A. Boumendjel, A. McLeer-Florin, P. Champelovier, D. Allegro, D. Muhammad,
F. Souard, M. Derouazi, V. Peyrot, B. Toussaint, J. Boutonnat, A novel chalcone
derivative which acts as a microtubule depolymerising agent and an inhibitor
of P-gp and BCRP in in-vitro and in-vivo glioblastoma models, BMC Cancer 9
[12] For an overview on the bioactivity of chalcones, consult: a) B.I. Roman,
T.S.A. Heugebaert, M. Bracke, C.V.O. Stevens, Assessment of the antineoplastic
potential of chalcones in animal models, Curr. Med. Chem. 20 (2013)
b) M.L. Go, X. Wu, X.L. Liu, Chalcones: an update on cytotoxic and chemo-
[25] V.S. Parmar, M.E. Bracke, J. Philippe, J. Wengel, S.C. Jain, C.E. Olsen, K.S. Bisht,
N.K. Sharma, A. Courtens, S.K. Sharma, K. Vennekens, V. Van Marck, S.K. Singh,
N. Kumar, A. Kumar, S. Malhotra, R. Kumar, V.K. Rajwanshi, R. Jain,
M.M. Mareel, Anti-invasive activity of alkaloids and polyphenolics in vitro,
[26] D.H.B. Ripin, M. Vetelino, 2-Methyltetrahydrofuran as an alternative to
[27] a) M. Cuendet, C.P. Oteham, R.C. Moon, J.M. Pezzuto, Quinone reductase in-
duction as a biomarker for cancer chemoprevention, J. Nat. Prod. 69 (2006)
b) M. Cuendet, J. Guo, Y. Luo, S. Chen, C.P. Oteham, R.C. Moon, R.B. van
Breemen, L.E. Marler, J.M. Pezzuto, Cancer chemopreventive activity and
metabolism of isoliquiritigenin, a compound found in licorice, Cancer Prev.
[28] a) C. Mathes, QPatch: the past, present and future of automated patch clamp,
[13] A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin,
J. Dearden, P. Gramatica, Y.C. Martin, R. Todeschini, V. Consonni, V.E. Kuz’min,
R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richard,
A. Tropsha, QSAR modeling: where have you been? Where are you going to?
[14] a) T. Fujita, J. Iwasa, C.A. Hansch, New substitution constant,
p, derived from
partition coefficients, J. Am. Chem. Soc. 86 (1964) 5175e5180, http://
b) C. Hansch, R.W. Taft, A survey of hammet substituent constants and reso-
[15] S. Bhagat, R. Sharma, D.M. Sawant, L. Sharma, A.K. Chakraborti, LiOH.H2O as a
novel dual activation catalyst for highly efficient and easy synthesis of 1,3-
diaryl-2-propenones by Claisen-Schmidt condensation under mild condi-
tions, J. Mol. Cat.
[16] a) D. Young, D. Martin, R. Venkatapathy, P. Harten, Are the chemical structures
in your QSAR correct? QSAR Comb. Sci. 27 (2008) 1337e1345, http://
A
b) W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie,
S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm,
T.G. Hammond, Relationships between preclinical cardiac electrophysiology,
clinical QT interval prolongation and torsade de pointes for a broad range of
drugs: evidence for a provisional safety margin in drug development, Car-
c) A. Harvey, J.B.J. Baell, N. Toovey, D. Homerick, H. Wulff, A new class of
blockers of the voltage-gated potassium channel Kv1.3 via modification of the
4- or 7-position of khellinone, J. Med. Chem. 49 (2006) 1433e1441, http://
b) D. Fourches, E. Muratov, A. Tropsha, Trust, but verify: on the importance of
chemical structure curation in cheminformatics and QSAR modeling research,
c) M.M. Olah, C.G. Bologa, T.I. Oprea, Strategies for compound selection, Curr.
Drug Discov. Technol.
1
d) O.V. Yarishkin, H.W. Ryu, J.Y. Park, M.S. Yang, S.G. Hong, K.H. Park, Sulfonate
chalcone as new class voltage-dependent Kþ channel blocker, Bioorg. Med.
[29] a) M.H. Richards, Rat hippocampal muscarinic autoreceptors are similar to the
M2 (cardiac) subtype: comparison with hippocampal M1, atrial M2 and ileal
[17] a) A.R. Katritzky, M. Karelson, R. Petrukhin, CODESSA Pro 1.0, Comprehensive
Descriptors for Structural and Statistical Analysis, University of Florida, 2001.
b) A.R. Katritzky, Z. Wang, S. Slavov, M. Tsikolia, D. Dobchev, N.G. Akhmedov,
C.D. Hall, U.R. Bernier, G.G. Clark, K.J. Linthicum, Synthesis and bioassay of
improved mosquito repellents predicted from chemical structure, Proc. Natl.
c) A.R. Katritzky, S.H. Slavov, D.A. Dobchev, M. Karelson, QSAR modeling of the
antifungal activity against Candida albicans for a diverse set of organic com-
b) S. Whitebread, J. Hamon, D. Bojanic, L. Urban, Keynote review: In vitro
safety pharmacology profiling: an essential tool for successful drug develop-
[30] a) C. Khanna, K. Hunter, Modeling metastasis in vivo, Carcinogenesis 26
[18] Organisation for Economic Co-Operation and Development, OECD Principles